Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors

Purpose: Checkpoint inhibitors have significantly improved treatment of metastatic melanoma. However, 40–60% of patients do not respond to therapy, emphasizing the need for better predictive biomarkers for treatment response to immune checkpoint inhibitors. Prorammed death-ligand 1(PD-L1) expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Jesper Geert, Madsen, Anne Tranberg, Gammelgaard, Kristine Raaby, Aggerholm-Pedersen, Ninna, Sørensen, Boe Sandahl, Øllegaard, Trine Heide, Jakobsen, Martin Roelsgaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353055/
https://www.ncbi.nlm.nih.gov/pubmed/32486146
http://dx.doi.org/10.3390/cancers12061414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353055/
https://www.ncbi.nlm.nih.gov/pubmed/32486146
http://dx.doi.org/10.3390/cancers12061414

Ejemplares similares